To Create and Deliver the New Standard of Care in Sterile Reprocessing™

Corporate Presentation | May 20191

The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve

certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the Company‘s limited history of sales or distribution, the evolution of demand for the

Company‘s products and services, the efficacy of sales and marketing plans including whether or not the Company‘s customers commit to purchases, the success of sales and marketing relationships with the

Company‘s partners and suppliers, the ability of the Company to obtain the required regulatory clearance to market its products on a worldwide basis, the outcome of patent applications, the condition of the

financial markets, the ability of the Company to attract capital and other financial and other risks and uncertainties.

Risks and uncertainties about the Company’s business are more fully discussed in the disclosure materials filed with the securities regulatory authorities in Canada, which are available on SEDAR under the issuer

profile of the Company at www.sedar.com. You are urged to read these materials.

Although management of the Company believes that the conclusions, estimates or projections reflected in such forward-looking information are reasonable and represent the Company’s conclusions, estimates

or projections at this time, such information involves unknown risks and uncertainties which may cause the Company’s actual results to differ materially from the Company’s conclusions, estimates or projections

expressed or implied by such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we do not undertake to update any

forward-looking statement.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

All Dollars in USD, unless noted otherwise.

US Pats. No. 9,101,679 / 9,474,815 / 9,480,763 / 9,480,765 / 9,814,795US Pat. Applications No. 14/820,965; 15/247,450 Canada 2,767,726 / 2,808,561EU Pat. EP 2,601,976; EP2,609,937; EP2,482,859; EP2,601,979Japan Pat. 5,480,975; 5,785,208; 5,785,211; 5,855,045; 6,141,950Corresponding patents granted or pending in other countries

TSX:TOS

Important Cautions Regarding Forward Looking Statements and Other Disclosures

STERIZONE®

registered trademarks of TSO3 Inc.

© TSO3 Inc., 2019. All rights reserved for all countries. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc.2

To Create and Deliver The New Standard of CareIn Sterile Reprocessing™

A Sterile Device for Every Patient

VISION. PURPOSE.

3

TSX:TOS4

One Disruptive Technology – Two Large Markets

Process/ Technology

1) The American Hospital Association, US Dept. of Health and Human Services, 2) Statistica.com 2015 3) Eurostat 4) Global Low Temperature Sterilization Market: Industry Analyst & Outlook. Koncept Analytics. January 2017 5) Centers for Disease Control and Prevention 6) US Food & Drug Administration 7) Markets and Markets, June 2016 8) Becker’s GI & Endoscopy “35 Statistics About GI/Endoscopy”

OR/CSSD$6.0B+7

GI50M+

Procedures/year8

Operating Room & Central Sterile Supply Department

U.S. ~10,000 Hospitals & Ambulatory Surgery Centers1

Canada ~1,400 Hospitals2

Europe ~15,000 Hospitals3

Installed base of 30,000 units4

Gastrointestinal

~15M colonoscopies performed annually5

>500,000 ERCP Procedures (endoscopic retrograde cholangiopancreatographies) performed annually6

Established Base Business Emerging Opportunity

TSX:TOS

1. Insert Room Temperature Instruments Into a Warm Chamber

2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time

3. Micro Condensation Forms on the Instruments

Breakthrough Technologies /// 201 Patents + Patents Pending Worldwide

Dual Sterilants

5

Condensation Layer Dynamic Sterilant Delivery SystemTM

TSX:TOS66

Capital Equipment Sales

1-4 units per facility

Higher-Margin Proprietary Consumables

* Based on long term Company Estimates. This illustration is based on assumptions and uncertainties as well as on management’s estimate of future events. Recent capital equipment selling prices have been and may continue to be lower than these amounts and actual results may differ significantly from the above illustration due to pricing promotions, customer usage patterns, outsourcing and other material variables. Not all customers enter into service contracts. The Company has limited sales history and there is no guarantee that it will achieve the results illustrated herein. Refer to additional risk factors contained in TSO3‘s disclosure materials filed with the securities regulatory authorities.

Service Contracts

~10% of Capital Price/Year

Potential Revenue Per US Customer*(Assuming 2 units, 10 Yr Product Life)

$200k-$300k

$20k-$30k/Sterilizer/Year

$12k-21k/Sterilizer/Year

Approx.$0.9m-$1.2m

Revenue Opportunity per

Customer*

Value of a Customer - Long Term Model

“Razor”

“Razorblades”

TSX:TOS7

New Metric: Cost per Instrument Sterilized, not Cost per Cycle

Competition STERIZONE® VP4 Sterilizer

Saves up to 50% in Operating Costs

2 STERIZONE® VP4 Sterilizers = 3+ of the Competition in Throughput

One of the Least Expensive Options In the Market Today

* Actual customer results. Results may vary depending on the customer and use profile.

Proven Value Proposition*

TSX:TOS

Disruptive Technology for OR Support

8

The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone.

Features Advantages Benefits

• Dual Chemistry

• Dynamic Delivery

• Large Capacity

• Lowest Cost per Instrument Sterilized

• Improved Operating and Service Costs

• Capital Cost Avoidance

• Expandability

• Leverage Existing Hospital Instrument Inventory

• Reduce HAI/reputational Risk

• Simple Single Cycle Operation

• Large Loads

• Mixed Loads

• Lower Cost

• Lower Risk

• Higher Throughput

• Ability to Process Full Instrument Sets

• Up to 1/3 fewer machines and cycles

TSX:TOS9

“We had 4 [competitor] Sterilizers, now we have 2 STERIZONE® VP4 Sterilizers.”

“VP4 cost less than [competitor] in long run”

“Service Expansion: added sleep center, ENT scopes, endoscopy reprocessing, neurosurgeon…”

Proven Value Proposition – Independent of Customer Size

“STERIZONE® VP4 50% less cost per instrument sterilized than competitor”

“Decreased Number of Cycles”

STERIZONE® VP4 Sterilizer is 3 times more efficient than competitor

1-200 Beds 600+ Beds201-600 Beds

* Based on actual 2017 customer surveys as compared to competitive low temperature hydrogen peroxide sterilizers. Results will vary depending on the customer and use profile.

Fewer Cycles Fewer Sterilizers Better Efficiency

TSX:TOS10

Commercialization Approach - CSSD

SUPPORT WITH DIRECT SALES, CLINICAL AND

TECHNICAL PERSONNEL

LEVERAGE EARLY ADOPTERS

• Name-brand user-base and references

• <200 beds to >1,000 beds+

INCREASE MARKET AWARENESS

• >5,000 Targeted Customers

• Value Proposition Selling

ESTABLISH STRONG CUSTOMER

TARGETING METRICS

• High Use Facilities

• Heavy Orthopedic and Robotic Surgical Centers

• Heavy Industry and Society Presence

• Trained in-house Personnel

• Shipment and Installation backlog

TSX:TOS

Goal to sell 200+ units in inventory

450+ opportunities

identified

~5,000 accounts targeted

11

Sales and Marketing Activity

As of March 27, 2019. “Units” = STERIZONE VP4 Sterilizers. “Sold” = Units for which POs or Commitment Indications were received directly or indirectly from end users.

75 Units Installed

> 30 Units Sold in Last Six Months

>110 Units Sold

• Sell Direct to End Users

10 Sales Representatives

Signed Partners/Agents

• GPO and IDN Contracts and System Sales

• Strategic Pricing: Lower ASPs for Speed

• New Approaches

Cost of Ownership Tools

Digital Ads

Trade Shows

TSX:TOS12

Endoscopy Sterilization – A Greenfield Opportunity

Process/ Technology

OR/CSSD$6.0B+7

GI50M+

Procedures/year8

Operating Room & Central Sterile Supply Department

Gastrointestinal

~15M colonoscopies performed annually5

>500,000 ERCP Procedures (endoscopic retrograde cholangiopancreatographies) performed annually6

Established Base Business Emerging Opportunity

1) The American Hospital Association, US Dept. of Health and Human Services, 2) Statistica.com 2015 3) Eurostat 4) Global Low Temperature Sterilization Market: Industry Analyst & Outlook. Koncept Analytics. January 2017 5) Centers for Disease Control and Prevention 6) US Food & Drug Administration 7) Markets and Markets, June 2016 8) Becker’s GI & Endoscopy “35 Statistics About GI/Endoscopy”

U.S. ~10,000 Hospitals and Ambulatory Surgery Centers1

Canada ~1,400 Hospitals2

Europe ~15,000 Hospitals3

Installed base of 30,000 units4

TSX:TOS

Modernizing GI Endoscope Reprocessing

13

“Despite reprocessing in accordance with US guidelines, viable microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to ensure successful decontamination.

“Residual contamination was detected on multiple components after reprocessing colonoscopes and EGDs in accordance with guidelines…viable microbes were recovered from patient-ready endoscopes (i.e., 64% post-HLD, 9% post-storage).”

- American Journal of Infection Control (with Mayo Clinic), 2015

“Strong Evidence for Sterilization of Endoscopes

Presented at Stakeholder Meeting”

- AAMI, September 2017

Decades old processes with only incremental improvement

“In an ominous sign for patient safety, 71 percent of reusable medical scopes deemed ready for use on patients tested positive for bacteria at three major U.S. hospitals, according to a new study.

- American Journal of Infection Control, 2018

TSX:TOS

Technology Advancement

Patient and Medical Facility Demand

Regulatory Change

• Patient Safety

• Litigation

• Cost Reduction

• STERIZONE® VP4 Sterilizer

• FDA Regulation Advancement

• Industry Dialogue and Guidelines

How Shifts Happen

= MarketChangeMarketChange

14

TSX:TOS

TSO3 Obtains Expanded Endoscope Clearances

15

Source: Olympus America Inc.

May 9, 2018 - TSO3 received FDA 510(k) clearance for the terminal sterilization of multi-channeled flexible endoscopes using the Company’s STERIZONE® VP4 Sterilizer

• Hospitals can terminally sterilize gastrointestinal endoscopes within the cleared intended use

• Includes certain colonoscopes, duodenoscopes and gastroscopes (see claims).

STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) with inside diameters of 1.2mm or more and lengths of 1955mm or less, or 1.45mm or more and lengths of 3500mm or less (see claims).

TSX:TOS16

Recent Customer Activity

Altru Health System Improves Patient Care with Expanded Use of Cutting-Edge Sterilization Technology

June 15, 2018 - “Being the inaugural facility to offer terminal sterilization of endoscopes using the TSO3 technology, provides our patients with a level of safety above current best-practice standards in the industry,” says Stacie Avdem, Director of Surgical and Procedural Services at Altru Health System.

“Altru has achieved industry leading practices with centralization, cleaning verification, and borescope inspection in endoscope reprocessing. The ability to sterilize endoscopes, specifically duodenoscopes, is paramount to achieving our mission of delivering world-class care to the residents of our region. It shows our ongoing investment in and commitment to patient safety,” says Jenni Gibbs, Manager of Central Sterile Department at Altru Health System.

Next Generation Technology

Extensive Patent Portfolio

Razor/Razorblade Business Model

First-to-Market FDA-cleared Device for Terminal Sterilization of Colonoscopes, Duodenoscopes and Gastroscopes (see claims)

SUMMARY

Direct Commercialization Strategy

Growing Installation Base

TSX:TOS17

TSX:TOS

Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise

18

$0.3

$0.4

$0.8

$1.1

$1.0

Q1-18 Q2-18 Q3-18 Q4-18 Q1-19

Quarterly Revenue$ Millions US

Stock Price (At May 3, 2019 close) $0.32

52 Week High - Low $1.15 - $0.28

Shares Outstanding (May 3, 2019) 93,465,238

Average Daily Volume (50 days) 132.17 k

Market Capitalization $29.9 M

Institutional Holdings ≈ 15%

Total Revenue - FY 2018Q1 2019

$2.5 M$1.1 M

Cash and Equivalents (March 31, 2019)

$11.3 M

Chart source: TMX Infosuite

19